Back to All Events

2017 ALS Virtual Research Forum


A free, two-day, webinar featuring world-class researchers in the field of ALS

Wednesday, August 9 and Thursday, August 10, 2017
9 a.m. – 3 p.m. 

Hosted by: Dr. David Taylor
VP Research, ALS Canada

For a disease like ALS that has no cure and few effective treatments, research is a tremendous source of hope. For the second year running, the ALS Canada Research Program is presenting a free Virtual Research Forum open to anyone interested in learning more about some of the ALS research currently underway and therapies in development. Hosted by Dr. David Taylor, VP Research at ALS Canada, the Virtual Research Forum will feature more than twenty speakers and panelists and will take place over two days.

How to attend: All you need to participate is a computer with internet connection and audio capabilities via a telephone or computer. Advance registration is recommended because spots are limited. Please note that you must register separately for each day. You can attend as many or as few sessions as you like, and you can sign on and off as suits your schedule.

The Virtual Research Forum will be conducted in English, with two speakers – Bastien Paré from Laval University and Elsa Tremblay from l’Université de Montréal – who are able to take questions in French. We will be identifying future opportunities to offer research updates in both official languages. See below for an agenda to help you plan your attendance. As the agenda is finalized we will post updates on Facebook and Twitter to keep you up to date.

Register now for the Virtual Research Forum: Wednesday, August 9 and Thursday, August 10. For more information, please contact research@als.ca.

Agenda

Wednesday August 9
Register now

11:00 – 11:05 a.m.
Introduction by Dr. David Taylor: Welcoming Remarks
11:05 a.m. – 12:00 p.m.
*Dr. Michael Strong, Western University: ALS/FTD Overview
12:00 – 12:20 p.m.
*Dr. Lawrence Korngut, University of Calgary: Pimozide for the treatment of ALS
12:20 – 12:40 p.m.
* Dr. Mark Ware, McGill University: Cannabis study
12:40 – 1:00 p.m.
* Dr. Christen Shoesmith, London Health Sciences Centre: Canadian ALS Best Practice Recommendations
1:00 – 1:30 p.m.
AB Science, Pharmaceutical Company: Masitinib for the treatment of Amyotrophic Lateral Sclerosis (ALS) – Preclinical overview of clinical development
1:30 – 3:00 p.m.
Clinical Roundtable: Dr. Wendy Johnston (University of Alberta), Dr. Colleen O’Connell (Dalhousie University), Dr. Angela Genge (Montreal Neurological Institute), Dr. Christen Shoesmith (London Health Sciences Centre), etc.
3:00 – 3:30 p.m.
BrainStorm: NurOwn trials
3:30 – 4:00 p.m.
Cytokinetics, Biotechnology Company: Tirasemtiv trials
4:00 – 5:00 p.m.
Dr. Richard Bedlack, Duke Institute for Brain Sciences: Lazarus by Lunasin? Untangling an ALS X-file

Research projects marked with an asterisk (*) have been funded thanks to the generous support of donors across Canada and the provincial ALS societies.

Agenda: Thursday August 10
Register now

11:00 – 11:30 a.m.
Introduction by Dr. David Taylor: Ice Bucketiology
11:30 – 11:50 a.m.
*Bastien Paré, Université Laval: ALS skin
11:50 a.m. – 12:10 p.m.
*Dr. Martin Duennwald, Western University: ALS yeast
12:10 – 12:30 p.m.
*Dr. Carl Laflamme, McGill University: Toward enhanced understanding of the function C9ORF72/SMCR8 in autophagy
12:30 – 12:50 p.m.
Dr. Phil McGoldrick, University of Toronto: C9 work/nucleocytoplasmic trafficking
12:50 – 2:20 p.m.
Preclinical Roundtable: Dr. Ian Mackenzie (University of British Columbia), Dr. Christine Vande Velde (Université de Montréal) etc.
2:20 – 2:40 p.m.
Dr. Neil Cashman, University of British Columbia: Protein misfolding in ALS
2:40 – 3:00 p.m.
Dr. Matthew Miller, McMaster University: Viral response mechanisms
3:00 – 3:20 p.m.
*Elsa Tremblay, Université de Montréal: Neuromuscular junction
3:20 – 3:40 p.m.
*Dr. Kelvin Jones, University of Alberta: Exercise study ALS
3:40 – 4:50 p.m.
TBA
4:50 – 5:00 p.m.
Dr. David Taylor: Wrap-Up

Research projects marked with an asterisk (*) have been funded thanks to the generous support of donors across Canada and the provincial ALS societies.